Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Doxorubicin/Cyclophosphamide then Paclitaxel and Adjuvant XMN in Breast Cancer
NCT00194779Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2003
- Primary completion
- Jun 2010
- Modality
- Irreversible Covalent Inhibitors, Stealth (PEGylated) Liposomes, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection, capecitabine, methotrexate and 1 more in breast cancer, sponsored by University of Washington. Primary endpoint: Pathologic Complete Response up to 16 weeks. Started Oct 2003; status: completed.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injectioncapecitabinemethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00194779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00194779.